Search

Your search keyword '"Mitkovskaya, Natalya P."' showing total 7 results
Start Over Author "Mitkovskaya, Natalya P."
7 results on '"Mitkovskaya, Natalya P."'

1. Nutraceutical approaches to non-alcoholic fatty liver disease (NAFLD): A position paper from the International Lipid Expert Panel (ILEP)

Author

Acosta, Julio, Al-Khnifsawi, Mutaz, Alnouri, Fahad, Amar, Fahma, Atanasov, Atanas G., Bajraktari, Gani, Banach, Maciej, Gouni-Berthold, Ioanna, Bhaskar, Sonu, Bielecka-Dąbrowa, Agata, Bjelakovic, Bojko, Bruckert, Eric, Bytyçi, Ibadete, Cafferata, Alberto, Ceska, Richard, Cicero, Arrigo F.G., Chlebus, Krzysztof, Collet, Xavier, Daccord, Magdalena, Descamps, Olivier, Djuric, Dragan, Durst, Ronen, Ezhov, Marat V., Fras, Zlatko, Gaita, Dan, Hernandez, Adrian V., Jones, Steven R., Jozwiak, Jacek, Kakauridze, Nona, Kallel, Amani, Katsiki, Niki, Khera, Amit, Kostner, Karam, Kubilius, Raimondas, Latkovskis, Gustavs, John Mancini, G.B., David Marais, A., Martin, Seth S., Martinez, Julio Acosta, Mazidi, Mohsen, Mikhailidis, Dimitri P., Mirrakhimov, Erkin, Miserez, Andre R., Mitchenko, Olena, Mitkovskaya, Natalya P., Moriarty, Patrick M., Mohammad Nabavi, Seyed, Nair, Devaki, Panagiotakos, Demosthenes B., Paragh, György, Pella, Daniel, Penson, Peter E., Petrulioniene, Zaneta, Pirro, Matteo, Postadzhiyan, Arman, Puri, Raman, Reda, Ashraf, Reiner, Željko, Radenkovic, Dina, Rakowski, Michał, Riadh, Jemaa, Richter, Dimitri, Rizzo, Manfredi, Ruscica, Massimiliano, Sahebkar, Amirhossein, Serban, Maria-Corina, Shehab, Abdullah M.A, Shek, Aleksandr B., Sirtori, Cesare R., Stefanutti, Claudia, Tomasik, Tomasz, Toth, Peter P., Viigimaa, Margus, Valdivielso, Pedro, Vinereanu, Dragos, Vohnout, Branislav, von Haehling, Stephan, Vrablik, Michal, Wong, Nathan D., Yeh, Hung-I, Zhisheng, Jiang, Zirlik, Andreas, Colletti, Alessandro, Mancini, John, Marais, David, Moriarty, Patrick, and Cicero, Arrigo Francesco Giuseppe

Published
2023
Full Text
View/download PDF

2. Nutraceutical approaches to non-alcoholic fatty liver disease (NAFLD): A position paper from the International Lipid Expert Panel (ILEP)

Author

Rizzo, Manfredi, primary, Colletti, Alessandro, additional, Penson, Peter E., additional, Katsiki, Niki, additional, Mikhailidis, Dimitri P., additional, Toth, Peter P., additional, Gouni-Berthold, Ioanna, additional, Mancini, John, additional, Marais, David, additional, Moriarty, Patrick, additional, Ruscica, Massimiliano, additional, Sahebkar, Amirhossein, additional, Vinereanu, Dragos, additional, Cicero, Arrigo Francesco Giuseppe, additional, Banach, Maciej, additional, Acosta, Julio, additional, Al-Khnifsawi, Mutaz, additional, Alnouri, Fahad, additional, Amar, Fahma, additional, Atanasov, Atanas G., additional, Bajraktari, Gani, additional, Bhaskar, Sonu, additional, Bielecka-Dąbrowa, Agata, additional, Bjelakovic, Bojko, additional, Bruckert, Eric, additional, Bytyçi, Ibadete, additional, Cafferata, Alberto, additional, Ceska, Richard, additional, Cicero, Arrigo F.G., additional, Chlebus, Krzysztof, additional, Collet, Xavier, additional, Daccord, Magdalena, additional, Descamps, Olivier, additional, Djuric, Dragan, additional, Durst, Ronen, additional, Ezhov, Marat V., additional, Fras, Zlatko, additional, Gaita, Dan, additional, Hernandez, Adrian V., additional, Jones, Steven R., additional, Jozwiak, Jacek, additional, Kakauridze, Nona, additional, Kallel, Amani, additional, Khera, Amit, additional, Kostner, Karam, additional, Kubilius, Raimondas, additional, Latkovskis, Gustavs, additional, John Mancini, G.B., additional, David Marais, A., additional, Martin, Seth S., additional, Martinez, Julio Acosta, additional, Mazidi, Mohsen, additional, Mirrakhimov, Erkin, additional, Miserez, Andre R., additional, Mitchenko, Olena, additional, Mitkovskaya, Natalya P., additional, Moriarty, Patrick M., additional, Mohammad Nabavi, Seyed, additional, Nair, Devaki, additional, Panagiotakos, Demosthenes B., additional, Paragh, György, additional, Pella, Daniel, additional, Petrulioniene, Zaneta, additional, Pirro, Matteo, additional, Postadzhiyan, Arman, additional, Puri, Raman, additional, Reda, Ashraf, additional, Reiner, Željko, additional, Radenkovic, Dina, additional, Rakowski, Michał, additional, Riadh, Jemaa, additional, Richter, Dimitri, additional, Rizzo, Manfredi, additional, Serban, Maria-Corina, additional, Shehab, Abdullah M.A, additional, Shek, Aleksandr B., additional, Sirtori, Cesare R., additional, Stefanutti, Claudia, additional, Tomasik, Tomasz, additional, Viigimaa, Margus, additional, Valdivielso, Pedro, additional, Vohnout, Branislav, additional, von Haehling, Stephan, additional, Vrablik, Michal, additional, Wong, Nathan D., additional, Yeh, Hung-I, additional, Zhisheng, Jiang, additional, and Zirlik, Andreas, additional

Published
2023
Full Text
View/download PDF

3. Impact of nutraceuticals on markers of systemic inflammation: Potential relevance to cardiovascular diseases – A position paper from the International Lipid Expert Panel (ILEP)

Author

Ruscica, Massimiliano, primary, Penson, Peter E., additional, Ferri, Nicola, additional, Sirtori, Cesare R., additional, Pirro, Matteo, additional, Mancini, G.B. John, additional, Sattar, Naveed, additional, Toth, Peter P., additional, Sahebkar, Amirhossein, additional, Lavie, Carl J., additional, Wong, Nathan D., additional, Banach, Maciej, additional, Acosta, Julio, additional, Al-Khnifsawi, Mutaz, additional, Alnouri, Fahad, additional, Amar, Fahma, additional, Atanasov, Atanas G., additional, Bajraktari, Gani, additional, Bhaskar, Sonu, additional, Bjelakovic, Bojko, additional, Bruckert, Eric, additional, Ceska, Richard, additional, Cicero, Arrigo F.G., additional, Collet, Xavier, additional, Descamps, Olivier, additional, Djuric, Dragan, additional, Durst, Ronen, additional, Ezhov, Marat V., additional, Fras, Zlatko, additional, Gaita, Dan, additional, Hernandez, Adrian V., additional, Jones, Steven R., additional, Jozwiak, Jacek, additional, Kakauridze, Nona, additional, Kallel, Amani, additional, Katsiki, Niki, additional, Khera, Amit, additional, Kostner, Karam, additional, Kubilius, Raimondas, additional, Latkovskis, Gustavs, additional, Marais, A. David, additional, Martin, Seth S., additional, Martinez, Julio Acosta, additional, Mazidi, Mohsen, additional, Mikhailidis, Dimitri P., additional, Mirrakhimov, Erkin, additional, Miserez, Andre R., additional, Mitchenko, Olena, additional, Mitkovskaya, Natalya P., additional, Moriarty, Patrick M., additional, Nabavi, Seyed Mohammad, additional, Nair, Devaki, additional, Panagiotakos, Demosthenes B., additional, Paragh, György, additional, Pella, Daniel, additional, Petrulioniene, Zaneta, additional, Postadzhiyan, Arman, additional, Puri, Raman, additional, Reda, Ashraf, additional, Reiner, Željko, additional, Radenkovic, Dina, additional, Rakowski, Michał, additional, Riadh, Jemaa, additional, Richter, Dimitri, additional, Rizzo, Manfredi, additional, Ruscica, Massimiliano, additional, Serban, Maria-Corina, additional, Shehab, Abdulla M.A., additional, Shek, Aleksandr B., additional, Stefanutti, Claudia, additional, Tomasik, Tomasz, additional, Viigimaa, Margus, additional, Valdivielso, Pedro, additional, Vinereanu, Dragos, additional, Vohnout, Branislav, additional, von Haehling, Stephan, additional, Vrablik, Michal, additional, Yeh, Hung-I, additional, Zhisheng, Jiang, additional, and Zirlik, Andreas, additional

Published
2021
Full Text
View/download PDF

5. Step‐by‐step diagnosis and management of the nocebo/drucebo effect in statin‐associated muscle symptoms patients: a position paper from the International Lipid Expert Panel(ILEP)

Author

Penson, Peter E., Bruckert, Eric, Marais, David, Reiner, Željko, Pirro, Matteo, Sahebkar, Amirhossein, Bajraktari, Gani, Mirrakhimov, Erkin, Rizzo, Manfredi, Mikhailidis, Dimitri P., Sachinidis, Alexandros, Gaita, Dan, Latkovskis, Gustavs, Mazidi, Mohsen, Toth, Peter P., Pella, Daniel, Alnouri, Fahad, Postadzhiyan, Arman, Yeh, Hung‐I, Mancini, G.B. John, Haehling, Stephan, Banach, Maciej, Acosta, Julio, Al‐Khnifsawi, Mutaz, Alnouri, Fahad, Amar, Fahma, Atanasov, Atanas G., Bajraktari, Gani, Banach, Maciej, Bhaskar, Sonu, Bytyçi, Ibadete, Bjelakovic, Bojko, Bruckert, Eric, Cafferata, Alberto, Ceska, Richard, Cicero, Arrigo F.G., Collet, Xavier, Daccord, Magdalena, Descamps, Olivier, Djuric, Dragan, Durst, Ronen, Ezhov, Marat V., Fras, Zlatko, Gaita, Dan, Hernandez, Adrian V., Jones, Steven R., Jozwiak, Jacek, Kakauridze, Nona, Kallel, Amani, Katsiki, Niki, Khera, Amit, Kostner, Karam, Kubilius, Raimondas, Latkovskis, Gustavs, Mancini, G.B. John, Marais, A. David, Martin, Seth S., Martinez, Julio Acosta, Mazidi, Mohsen, Mikhailidis, Dimitri P., Mirrakhimov, Erkin, Miserez, Andre R., Mitchenko, Olena, Mitkovskaya, Natalya P., Moriarty, Patrick M., Nabavi, Seyed Mohammad, Nair, Devaki, Panagiotakos, Demosthenes B., Paragh, György, Pella, Daniel, Penson, Peter E., Petrulioniene, Zaneta, Pirro, Matteo, Postadzhiyan, Arman, Puri, Raman, Reda, Ashraf, Reiner, Željko, Radenkovic, Dina, Rakowski, Michał, Riadh, Jemaa, Richter, Dimitri, Rizzo, Manfredi, Ruscica, Massimiliano, Sahebkar, Amirhossein, Sattar, Naveed, Serban, Maria‐Corina, Shehab, Abdullah M.A., Shek, Aleksandr B., Sirtori, Cesare R., Stefanutti, Claudia, Tomasik, Tomasz, Toth, Peter P., Viigimaa, Margus, Valdivielso, Pedro, Vinereanu, Dragos, Vohnout, Branislav, Haehling, Stephan, Vrablik, Michal, Wong, Nathan D., Yeh, Hung‐I, Zhisheng, Jiang, and Zirlik, Andreas

Abstract

Statin intolerance is a clinical syndrome whereby adverse effects (AEs) associated with statin therapy [most commonly statin‐associated muscle symptoms (SAMS)] result in the discontinuation of therapy and consequently increase the risk of adverse cardiovascular outcomes. However, complete statin intolerance occurs in only a small minority of treated patients (estimated prevalence of only 3–5%). Many perceived AEs are misattributed (e.g. physical musculoskeletal injury and inflammatory myopathies), and subjective symptoms occur as a result of the fact that patients expect them to do so when taking medicines (the nocebo/drucebo effect)—what might be truth even for over 50% of all patients with muscle weakness/pain. Clear guidance is necessary to enable the optimal management of plasma in real‐world clinical practice in patients who experience subjective AEs. In this Position Paper of the International Lipid Expert Panel (ILEP), we present a step‐by‐step patient‐centred approach to the identification and management of SAMS with a particular focus on strategies to prevent and manage the nocebo/drucebo effect and to improve long‐term compliance with lipid‐lowering therapy.

Published
2022
Full Text
View/download PDF

6. Long-term transportation noise exposure and incidence of ischaemic heart disease and stroke: a cohort study

Author

Pyko, Andrei, Andersson, Niklas, Eriksson, Charlotta, de Faire, Ulf, Lind, Tomas, Mitkovskaya, Natalya, O¨gren, Mikael, O¨stenson, Claes-Go¨ran, Pedersen, Nancy L, Rizzuto, Debora, Wallas, Alva Ka¨te, and Pershagen, Go¨ran

Abstract

BackgroundThere is limited evidence from longitudinal studies on transportation noise from different sources and development of ischaemic heart disease (IHD) and stroke.ObjectivesThis cohort study assessed associations between exposure to noise from road traffic, railway or aircraft and incidence of IHD and stroke.MethodsIn a cohort of 20 012 individuals from Stockholm County, we estimated long-term residential exposure to road traffic, railway and aircraft noise. National Patient and Cause-of-Death Registers were used to identify IHD and stroke events. Information on risk factors was obtained from questionnaires and registers. Adjusted HR for cardiovascular outcomes related to source-specific noise exposure were computed using Cox proportional hazards regression.ResultsNo clear or consistent associations were observed between transportation noise and incidence of IHD or stroke. However, noise exposure from road traffic and aircraft was related to IHD incidence in women, with HR of 1.11 (95% CI 1.00 to 1.22) and 1.25 (95% CI 1.09 to 1.44) per 10 dB Lden, respectively. For both sexes taken together, we observed a particularly high risk of IHD in those exposed to all three transportation noise sources at≥45 dB Lden, with a HR of 1.57 (95% CI 1.06 to 2.32), and a similar tendency for stroke (HR 1.42; 95% CI 0.87 to 2.32).ConclusionNo overall associations were observed between transportation noise exposure and incidence of IHD or stroke. However, there appeared to be an increased risk of IHD in women exposed to road traffic or aircraft noise as well as in those exposed to multiple sources of transportation noise.

Published
2019
Full Text
View/download PDF

7. A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis

Author

Rovin, Brad H., Solomons, Neil, Pendergraft, William F., Dooley, Mary Anne, Tumlin, James, Romero-Diaz, Juanita, Lysenko, Lidia, Navarra, Sandra V., Huizinga, Robert B., Adzerikho, Ihar, Mikhailova, Elena, Mitkovskaya, Natalya, Pimanov, Sergey, Soroka, Nikolay, Bogov, Boris Iliev, Deliyska, Boriana, Ikonomov, Valentin, Tilkiyan, Eduard, Almeida, Ruth, Jimenez, Fernando, Teran, Faud, Tchokhonelidze, Irma, Tsiskarishvili, Nino, Herrera Mendez, Maynor, Chavez Perez, Nilmo Noel, Loaeza, Arturo Reyes, Gutierrez Urena, Sergio Ramon, Romero Diaz, Juanita, Araiza Casillas, Rodolfo, Madero Rovalo, Magdalena, Niemczyk, Stanislaw, Sokalski, Antoni, Wiecek, Andrzej, Klinger, Marian, Bugrova, Olga V., Chernykh, Tatiana M., Kameneva, Tatiana R., Lysenko, Lidia V., Raskina, Tatiana A., ReshEtko, Olga V., Vezikova, Natalia N., Kropotina, Tatiana V., Maksudova, Adelya N., Marasaev, Vyacheslav, Dobronravov, Vladimir A., Gordeev, Ivan, EssAian, Ashot M., Frolov, Alexey, Jelacic, Rosa, Jovanovic, Dragan, Mitic, Branka, Pekovic, Gordana, Radovic, Milan, Radunovic, Goran, Carreira, Patricia, Diaz Gonzalez, Federico, Fulladosa, Xavier, Ucar, Eduardo, De Silva, Shamila, Herath, Chula, Hewageegana, Anura, Nazar, Abdul Latiff Mohamed, Wazil, A.W.M., Dudar, Iryna, Godlevska, Olga, Korneyeva, Svitlana, Vasylets, ViktoriIa, Sydor, Nataliya, Kolesnyk, Mykola, Parikh, Samir V., Olsen, Nancy, Ginzler, Ellen M., Tumlin, James A., Saxena, Amit, Saxena, Ramesh, Lafayette, Richard Alan, Pendergraft, William Franklin, Podoll, Amber S., Arrey-Mensah, Annie A., Bubb, Michael, Grossman, Jennifer, Oporta, Alejandro I., Nami, Alireza, Rahman, Md. Mujibur, Haq, Syed Atiqul, Chan, Tak Mao Daniel, Temy, Mok Mo Yin, Gomez, Harold Michael P., Bermas, James, Reyes, Bernadette Heizel, Hao, Llewellyn T., Roberto, Linda Charmaine, Amante, Eric, Navarra, Sandra V., Lanzon, Allan E., Choe, Jung-Yoon, Kang, Tae Young, Kim, Yon Su, Lee, Seung-Geun, Lee, Ji Soo, Jun, Jason Choo Chon, Vasudevan, Archana, Luo, Shue-Fen, Cheng, Tien-Tsai, Satirapoj, Bancha, and Noppakun, Kajohnsak

Abstract

Calcineurin inhibitors added to standard-of-care induction therapy for lupus nephritis (LN) may increase complete renal remission (CRR) rates. The AURA-LV study tested the novel calcineurin inhibitor voclosporin for efficacy and safety in active LN. AURA-LV was a Phase 2, multicenter, randomized, double-blind, placebo-controlled trial of two doses of voclosporin (23.7 mg or 39.5 mg, each twice daily) versus placebo in combination with mycophenolate mofetil (2 g/d) and rapidly tapered low-dose oral corticosteroids for induction of remission in LN. The primary endpoint was CRR at 24 weeks; the secondary endpoint was CRR at 48 weeks. Two hundred sixty-five subjects from 79 centers in 20 countries were recruited and randomized to treatment for 48 weeks. CRR at week 24 was achieved by 29 (32.6%) subjects in the low-dose voclosporin group, 24 (27.3%) subjects in the high-dose voclosporin group, and 17 (19.3%) subjects in the placebo group (OR=2.03 for low-dose voclosporin versus placebo). The significantly greater CRR rate in the low-dose voclosporin group persisted at 48 weeks, and CRRs were also significantly more common in the high-dose voclosporin group compared to placebo at 48 weeks. There were more serious adverse events in both voclosporin groups, and more deaths in the low-dose group compared to placebo and high-dose voclosporin groups (11.2%, 1.1%, and 2.3%, respectively). These results suggest that the addition of low-dose voclosporin to mycophenolate mofetil and corticosteroids for induction therapy of active LN results in a superior renal response compared to mycophenolate mofetil and corticosteroids alone, but higher rates of adverse events including death were observed.

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results